Literature DB >> 23174714

Methylenetetrahydrofolate reductase gene polymorphisms (677C > T and 1298A > C) in Egyptian patients with non-Hodgkin lymphoma.

Aml S Nasr1, Rania M Sami, Noha Y Ibrahim.   

Abstract

BACKGROUND: Folate metabolism plays an essential role in Deoxyribonucleic acid (DNA) synthesis and methylation processes. Deviations in the flux of the folate may affect the susceptibility to various cancers including lymphoma. AIM: The aim of this study was to investigate the genetic polymorphisms in 5, 10-methylenetetrahydrofolate reductase (MTHFR 677C/T and 1298A/C) and to evaluate its associations with the risk of Non Hodgkin lymphoma.
MATERIALS AND METHODS: The study included 50 patients with diffuse large B cell lymphoma (DLBCL) as well as 50 age matched apparently healthy volunteers (as control). All the subjects included in the study were genotyped for the detection of the MTHFR gene polymorphisms (677C > T and 1298A > C) by using restriction fragment length polymorphism (PCR-RFLP).
RESULTS: There were highly statistically significant differences between the 2 groups with respect to results of PCR-RFLP for MTHFR 677C→T polymorphism for CC genotype (P value = 0.001), statistically significant differences for CT (P value = 0.048) and TT (P value = 0.038) genotypes; however, no statistically significant differences regarding CC/CT or TT/CT alleles (P value = 0.052). Also, there were highly statistically significant differences between the patient and control groups with regards to the results of MTHFR1298 A/C polymorphism for the AA, AC genotypes as well as the AA/AC and CC/AC alleles (P value < 0.0001), and statistically significant difference regarding CC genotype (P value 0.0192).
CONCLUSION: In conclusion, this study demonstrated a significant association between the MTHFR polymorphisms and the risk of DLBCL. Thus the study could support that folate intake together with the genetic basis may help in modifying the risk to lymphoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23174714     DOI: 10.4103/0973-1482.103512

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

1.  Methodology for single nucleotide polymorphism selection in promoter regions for clinical use. An example of its applicability.

Authors:  Herlander Marques; José Freitas; Rui Medeiros; Adhemar Longatto-Filho
Journal:  Int J Mol Epidemiol Genet       Date:  2016-09-30

2.  Methylenetetrahydrofolate reductase gene polymorphisms association with the risk of diffuse large B cell lymphoma: a meta-analysis.

Authors:  Yun-Yu Sun; Li An; Yu-Lan Xie; Jing-Yan Xu; Jing Wang
Journal:  Tumour Biol       Date:  2013-06-28

3.  Genetic and epigenetic variants in the MTHFR gene are not associated with non-Hodgkin lymphoma.

Authors:  Gabrielle Bradshaw; Heidi G Sutherland; Emily T Camilleri; Rodney A Lea; Larisa M Haupt; Lyn R Griffiths
Journal:  Meta Gene       Date:  2015-10-22

4.  Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis.

Authors:  Jing He; Xiao-Yu Liao; Jin-Hong Zhu; Wen-Qiong Xue; Guo-Ping Shen; Shao-Yi Huang; Wei Chen; Wei-Hua Jia
Journal:  Sci Rep       Date:  2014-08-22       Impact factor: 4.379

5.  The SNP rs4846048 of MTHFR enhances the cervical cancer risk through association with miR-522: A preliminary report.

Authors:  Xinyue Zhou; Lili Shan; Jing Na; Ya Li; Jun Wang
Journal:  Mol Genet Genomic Med       Date:  2019-11-21       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.